Peptide record

TPDB25362

Antibacterial Anticancer Antiviral Toxicity standard
4 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25362
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia dbAMP 3.0 DRAMP DRAVP 2.0
standard
No
A 4-aa standard natural multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, dbAMP 3.0, DRAMP, and other sources, with an available 3D structural model.
Sequence
RVKR
Physicochemical Analysis
C23H47N11O5
ANDCEQGHILMFPSTWY
R
557.70
12.41
3
0
1
+3
2.68
-2.175
72.50
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
1
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
4
C23H47N11O5
557.70
12.41
+3
2.68
-2.175
Evidence Records 3 records
Evidence 1 Activity

Activity

50% Cell death
Toxicity
712.9 µM
Cytotoxic
50% Cell death | 712.9 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage. | Viruses | 2019
Evidence 2 Activity

Activity

50% Cytotoxicity
Toxicity
318.2 µM
Cytotoxic
50% Cytotoxicity | 318.2 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. | Cell Rep | 2020
Evidence 3 Activity

Activity

IC50
Toxicity
318.2 µM
Cytotoxic
Cytotoxicity: [Ref.31683742]Vero cells:CC50=712.9 µM.[Ref.33007239]Vero E6 cells:IC50=318.2 µM.

Source & Reference

NA
DRAMP
Liver Int. 2013 Sep 33(8):1230-8. ##Viruses. 2019 Oct 31 11(11):1011.##Cell Rep. 2020 Oct 13 33(2):108254.